<?xml version="1.0" encoding="UTF-8"?>
<p id="Par89">Adalimumab (Humira) was developed by BASF Bioresearch Corporation and Cambridge Antibody Technology. It was not only the first phage display-derived antibody granted a marketing approval, but adalimubab was also the first approved (2002) fully human mAb drug [
 <xref ref-type="bibr" rid="CR139">139</xref>]. Adalimumab binds and suppresses TNFα and is approved to treat inflammatory diseases, such as rheumatoid and psoriatic arthritis, Crohn’s disease, and psoriasis. Adalimumab is the world’s best-selling drug [
 <xref ref-type="bibr" rid="CR140">140</xref>] with sales of $19.9 billion in 2018 reported by AbbVie (Table 
 <xref rid="Tab2" ref-type="table">2</xref>). Cambridge Antibody Technology also identified human antibodies targeting BLYS (B lymphocyte stimulator) from phage display [
 <xref ref-type="bibr" rid="CR141">141</xref>]. BLYS, a member of the tumor necrosis factor superfamily of cytokines, induces B cell proliferation and differentiation that positively correlate with systemic lupus erythematosus (SLE). This anti-BLYS antibody was named belimumab and marketed as Benlysta by GlaxoSmithKline, becoming the first drug approved (2011) for the treatment of SLE [
 <xref ref-type="bibr" rid="CR142">142</xref>]. Founded in 1989, Cambridge Antibody Technology was acquired by AstraZeneca for $1.32 billion in 2006 [
 <xref ref-type="bibr" rid="CR143">143</xref>].
</p>
